Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities researchers at B. Riley issued their Q3 2025 earnings per share estimates for shares of Foghorn Therapeutics in a report released on Tuesday, September 16th. B. Riley analyst Y. Zhi forecasts that the company will earn ($0.33) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics' Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($1.02) EPS and FY2029 earnings at ($0.94) EPS.
Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03. The company had revenue of $7.56 million for the quarter, compared to analysts' expectations of $7.62 million.
Foghorn Therapeutics Trading Up 0.2%
Shares of FHTX stock traded up $0.01 during trading hours on Friday, reaching $4.99. 33,508 shares of the stock were exchanged, compared to its average volume of 124,922. Foghorn Therapeutics has a 12-month low of $2.94 and a 12-month high of $9.99. The company's 50-day moving average price is $5.36 and its 200-day moving average price is $4.66. The firm has a market capitalization of $282.08 million, a price-to-earnings ratio of -4.19 and a beta of 3.05.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of FHTX. Nuveen LLC acquired a new stake in shares of Foghorn Therapeutics during the first quarter worth $221,000. Bank of America Corp DE boosted its holdings in shares of Foghorn Therapeutics by 14.5% in the 4th quarter. Bank of America Corp DE now owns 31,662 shares of the company's stock valued at $149,000 after acquiring an additional 4,002 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Foghorn Therapeutics by 44.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 100,367 shares of the company's stock worth $474,000 after buying an additional 30,671 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in Foghorn Therapeutics by 9.3% during the first quarter. Raymond James Financial Inc. now owns 2,218,352 shares of the company's stock worth $8,097,000 after buying an additional 188,969 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in Foghorn Therapeutics during the fourth quarter worth $61,000. Hedge funds and other institutional investors own 61.55% of the company's stock.
Foghorn Therapeutics Company Profile
(
Get Free Report)
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
See Also
Before you consider Foghorn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.
While Foghorn Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
